Johnson & Johnson is collaborating with Vaxart on a universal or

Johnson & Johnson is collaborating with Vaxart on a universal oral flu vaccine. This vaccine is only in preclinical testing right now, but results from these tests should be on the way this summer. Vaxart also reported positive results from a phase 1 study of its oral norovirus vaccine. The company, however, has put the program on hold while it looks for a partner for advancing the development of that vaccine.

Vaxart (NASDAQ:VXRT) was upgraded by stock analysts at BidaskClub from a "hold" rating to a "buy" rating in a research note issued on Tuesday, BidAskClub reports.